David Pernock

David Pernock has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Eagle Pharmaceuticals, Inc. and Fibrocell Science, Inc. In total, 15 filings cover trades dated from 2 December 2016 to 2 February 2021.

On the market, this insider has only ever bought: 5 purchases, €96k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 10 share grants.

In size, the median ticket on the buying side is €15k. Across 4 purchases, this insider has always bought alone, with no colleague buying within 30 days. Ninety days after publication, 3 purchases show a median change of -30.2%, with the price up in 0% of them. Past outcomes like these are no guarantee of what comes next.

On 4 February 2021 came the latest disclosure, a share grant in Eagle Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 3,444 days ago, on 19 May 2017. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.